Cytokinetics Inc (CYTK) Hedge Fund Ownership (Q2 2026)

Cytokinetics Inc (CYTK)

479 + Investors. Track Smart Money conviction in CYTK. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CYTK

Based on 485 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

485 hedge funds hold CYTK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +53% more funds vs a year ago

fund count last 6Q

+168 new funds entered over the past year (+53% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 66% buying

338 buying175 selling

Last quarter: 338 funds were net buyers (95 opened a brand new position + 243 added to an existing one). Only 175 were sellers (116 trimmed + 59 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+13 vs last Q)

new funds entering per quarter

Funds opening a new CYTK position: 102 → 103 → 82 → 95. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 20% medium ■ 28% new

252 out of 485 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +39% but shares only +14% — price-driven

Value

+39%

+13%

Last quarter: the total dollar value of institutional holdings rose +39%, but actual share count only changed +14%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

➡️

Steady discovery — ~95 new funds/quarter

30 → 102 → 103 → 82 → 95 new funds/Q

New funds entering each quarter: 102 → 103 → 82 → 95. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 61% veterans vs 28% newcomers

■ 61% veterans ■ 11% 1-2yr ■ 28% new

Entry-cohort mix of 508 holders: 309 (61%) are 2+ year veterans, 55 entered 1–2 years ago, and 144 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 55% AUM from top-100 funds

55% from top-100 AUM funds

64 of 479 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.2

out of 10

Moderate Exit Risk

Exit risk score 4.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	479	449	6.68%
13F Shares	179M	157M	13.71%
Total Value	$12.47B	$8.97B	39.1%
New Positions	95	82	+13
Increased Positions	232	185	+47
Closed Positions	59	65	-6
Reduced Positions	108	131	-23
Total Calls	18	32	-43.75%
Total Puts	11	20	-45.0%
PUT/CALL Ratio	0.61	0.62	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

479

449

6.68%

13F Shares

179M

157M

13.71%

Total Value

$12.47B

$8.97B

39.1%

New Positions

+13

Increased Positions

232

185

+47

Closed Positions

-6

Reduced Positions

108

131

-23

Total Calls

-43.75%

Total Puts

-45.0%

PUT/CALL Ratio

0.61

0.62

Bullish

Institutional Holders (2026 Q2)

479 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CYTK. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CYTK holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Royalty Pharma Sub-Manager, LLC	34.52%	980,392	$83.5M
2	Foresite Capital Management IV, LLC	20.98%	714,695	$60.9M
3	Sarissa Capital Management LP	10.95%	228,623	$19.5M
4	Checkpoint Capital L.P.	10.38%	475,000	$40.5M
5	Melqart Asset Management (UK) Ltd	6.22%	767,525	$65.4M
6	Integral Health Asset Management, LLC	5.38%	1,600,000	$136.3M
7	GSK plc	4.82%	340,434	$29.0M
8	First Turn Management, LLC	4.81%	527,412	$44.9M
9	Trails Edge Capital Partners, LP	3.90%	288,089	$24.5M
10	Avoro Capital Advisors LLC	3.82%	4,999,999	$425.9M
11	Exome Asset Management LLC	3.16%	60,056	$5.1M
12	Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	3.08%	660,310	$56.3M
13	DAFNA Capital Management LLC	2.79%	171,998	$14.7M
14	Act Capital Management, LLC	2.64%	47,500	$4.0M
15	Sphera Funds Management LTD.	2.44%	219,987	$18.7M
16	Frazier Life Sciences Management, L.P.	2.15%	1,159,879	$98.8M
17	Polaris Capital Management, LLC	2.14%	266,900	$22.7M
18	Affinity Asset Advisors, LLC	2.12%	550,000	$46.9M
19	Mirador Capital Partners LP	2.11%	202,370	$17.2M
20	Rtw Investments, LP	2.08%	2,862,003	$243.8M
21	Ishara Investments LP	2.05%	32,800	$2.8M
22	Tri Locum Partners LP	2.03%	194,000	$16.5M
23	ADAR1 Capital Management, LLC	1.79%	457,907	$39.0M
24	Ironwood Investment Management LLC	1.67%	56,589	$4.8M
25	Seven Fleet Capital Management LP	1.66%	118,240	$10.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Cytokinetics Inc (CYTK)

What does the Smart Money Trend signal show for CYTK?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CYTK?

More buyers than sellers — 66% buying: Last quarter: 338 funds were net buyers (95 opened a brand new position + 243 added to an existing one). Only 175 were sellers (116 trimmed + 59 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CYTK holders?

Elite ownership — 55% AUM from top-100 funds: 64 of 479 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CYTK?

52% of holders stayed for 2+ years: 252 out of 485 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Cytokinetics Inc (CYTK)

Smart Money Signals — CYTK

Buying streak — 4 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +53% more funds vs a year ago

More buyers than sellers — 66% buying

More new buyers each quarter (+13 vs last Q)

52% of holders stayed for 2+ years

Value +39% but shares only +14% — price-driven

Steady discovery — ~95 new funds/quarter

Veteran-anchored — 61% veterans vs 28% newcomers

Elite ownership — 55% AUM from top-100 funds

Institutional Sentiment Summary — CYTK

Hedge Fund Ownership: CYTK

Market Analysis: CYTK

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CYTK

Hedge Fund Positioning: CYTK

Statistics: CYTK

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Cytokinetics Inc (CYTK)

Welcome to 13Foresight!